阅读说明：本技术 一种抗大肠杆菌性腹泻病蒙兽药及其制备方法 (Mongolian veterinary drug for resisting enterobacteriaceae diarrhea and preparation method thereof ) 是由 王纯洁 高瑞娟 敖日格乐 刘佳乐 田艳萍 高钰思 付鹤 杭盖巴特尔 包福祥 徐进 于 2021-08-11 设计创作，主要内容包括：本发明公开了一种抗大肠杆菌性腹泻病蒙兽药及其制备方法,该包括草乌叶、诃子、多叶棘豆、茜草、黑云香、甘松、大黄,上述7味药的质量比为2∶1∶1∶1∶1∶2∶2,本发明通过改善动物肠道菌群结构等,调节腹泻模型动物及靶动物的抗炎、免疫及肠道屏障作用,提高动物的抗菌、抗炎及肠道屏障功能,使大肠杆菌性腹泻发病率降低,进而提高幼畜存活率,提高经济效益。(The invention discloses a Mongolian veterinary drug for resisting enterobacteriaceae diarrhea and a preparation method thereof, wherein the Mongolian veterinary drug comprises 7 medicines of radix aconiti kusnezoffii, myrobalan, oxytropis lobata, madder, black cloud, nardostachys chinensis and rheum officinale, and the mass ratio of the 7 medicines is 2: 1: 2.)

1. A Mongolian veterinary drug for resisting enterobacteriaceae diarrhea is characterized in that: comprises 7 kinds of medicines of radix aconiti kusnezoffii, myrobalan, multi-leaf acanthopanax, madder, black cloud incense, nardostachys chinensis and rhubarb, and the mass ratio of the 7 kinds of medicines is 2: 1: 2.

2. The Mongolian veterinary drug for treating enterobacteriaceae diarrhea according to claim 1, wherein the Mongolian veterinary drug is characterized in that: the preferred mass of the black grass leaf, the myrobalan, the poincarpus lobata, the madder, the black sesame, the nardostachys chinensis and the rhubarb is 5g of the black grass leaf, 2.5g of the myrobalan, 2.5g of the poincarpus lobata, 2.5g of the madder, 2.5g of the black sesame, 5g of the nardostachys chinensis and 5g of the rhubarb.

3. A preparation method of a Mongolian veterinary drug for resisting enterobacteriaceae diarrhea is characterized by comprising the following steps:

mixing 5g of radix aconiti kusnezoffii, 2.5g of myrobalan, 2.5g of oxytropis leafata, 2.5g of madder, 2.5g of black sesame, 5g of nardostachys chinensis and 5g of rheum officinale in proportion, crushing, and blending in water or milk for taking.

4. The Mongolian veterinary drug for treating enterobacteriaceae diarrhea according to claim 3, wherein the Mongolian veterinary drug is characterized in that: the administration method of the Mongolian veterinary drug comprises the steps of carrying out continuous intragastric administration for 7d and 2 times/d at dosages of 10.0g/kg.b.w, 5.0g/kg.b.w and 2.5 g/kg.b.w.

Technical Field

The invention belongs to the technical field of preparation of Mongolian veterinary medicines, and particularly relates to a Mongolian veterinary medicine for resisting enterobacteriaceae diarrhea and a preparation method thereof.

Background

Colibacillosis is highly infectious and has high mortality, and diarrhea is a common clinical symptom of the colibacillosis and one of three causes of death related to infectious diseases and mainly affects young animals. The national animal health monitoring system shows that about 57.0% of sick calves die of diarrhea, the incidence rate of 10-day-old calves in China reaches 30.27%, the mortality rate is 4.73%, and the incidence rate of calves within 1 month in 12 months to 4 months is higher and reaches 18.87% -21.26%. In northwest areas including inner Mongolia, the detection rate of escherichia coli induced diarrhea positive is 35.90%, the detection rate of Xinjiang calf escherichia coli diarrhea is 51.30%, and antibiotics are the first choice of the antibiotics, so that the traditional Chinese medicine composition has the characteristics of rapid symptom relief, low cost, stable effect and the like. In order to seek economic and production benefits, farmers add antibiotics into the feed to improve the feed conversion rate and accelerate the growth of livestock and poultry. 9.7 ten thousand tons of antibiotics are used for livestock breeding every year in China, and account for about 46 percent of annual output. However, excessive use of antibiotics brings about a series of hidden dangers such as drug-resistant bacteria, variant ultrafine bacteria, allergy, flora disorder and the like. The drug resistance rate of 34 calf diarrhea escherichia coli doxycycline in a large-scale dairy farm in northern China is 100%, the drug resistance rate of ampicillin, streptomycin, azithromycin and compound sulfamethoxazole is over 80%, and 24 drug-resistant bacteria with the drug resistance of more than 10 are determined, and the drug resistance rate is 70.59%. No. 194 bulletin of rural areas of agriculture in 2019 enforces a regulation of forbidding the use of all growth-promoting drugs except traditional Chinese medicines in commercial feeds. Therefore, it is becoming important to develop new drugs that are green and can replace antibiotics.

Mongolian medicine is an important component of traditional Chinese medicine, experiences summary and intelligent crystallization in the fight against diseases for more than two thousand years, and absorbs part of basic theories of Tibetan medicine, Indian medicine and traditional Chinese medicine, thereby forming a unique theoretical system and a characteristic ethnic medicine system with diagnosis and treatment experience. Mongolian medicine considers that an organism consists of three elements and seven elements, wherein the three elements refer to three kinds of energy required by the organism, namely, Heyi, Hira and Ba Da do, and the seven elements refer to seven basic substances, namely essence, blood, meat, fat, bone, marrow and semen. The balance among the three and the seven elements regulates the health of the animal body. However, under the action of various pathogenic factors, three of the body are preponderant or partially debilitated, destroying the homeostasis of the body and causing diseases. The recovery of Mongolian medical observation is actually the process of regulating the prosperity and the defencence of the three roots to restore the balance. This is in line with physiological homeostasis theory.

Disclosure of Invention

The invention overcomes the defects in the prior art and provides a Mongolian veterinary drug for resisting enterobacteriaceae diarrhea and a preparation method thereof.

In order to solve the technical problems, the invention is realized by the following technical scheme:

a Mongolian veterinary drug for resisting enterobacteriaceae diarrhea comprises radix Linderae Caudatae, fructus Chebulae, radix Oxytropis myriophylli, radix Rubiae, herba Elephantopi Nigri, radix Et rhizoma Nardostachyos, and radix Et rhizoma Rhei, wherein the mass ratio of the 7 herbs is 2: 1: 2.

In the technical scheme, the mass of the wuweiye, the myrobalan, the echinocandin, the madder, the black Yunnan incense, the nardostachys root and the rhubarb is preferably 5g of the wuweiye, 2.5g of the myrobalan, 2.5g of the echinocandin, 2.5g of the madder, 2.5g of the black Yunnan incense, 5g of the nardostachys root and 5g of the rhubarb.

A preparation method of a Mongolian veterinary drug for resisting enterobacteriaceae diarrhea comprises the following steps:

mixing 5g of radix aconiti kusnezoffii, 2.5g of myrobalan, 2.5g of oxytropis leafata, 2.5g of madder, 2.5g of black sesame, 5g of nardostachys chinensis and 5g of rheum officinale in proportion, crushing, and blending in water or milk for taking.

In the technical scheme, the administration method of the Mongolian veterinary drug is to continuously perform intragastric administration for 7d and 2 times/d at dosages of 10.0g/kg.b.w, 5.0g/kg.b.w and 2.5 g/kg.b.w.

Compared with the prior art, the invention has the beneficial effects that:

by improving the intestinal flora structure of animals, adjusting the intestinal barrier function of diarrhea model animals and target animals, improving the antibacterial, anti-inflammatory and intestinal barrier functions of animals, reducing the incidence of colibacillosis diarrhea, further improving the survival rate and growth speed of young animals, and improving the economic benefit.

Drawings

FIG. 1 is a plot of species diversity and a cumulative box plot of species.

FIG. 2 groups of mice are based on PcoA and UPGAMA analysis of Bray-Curtis cecal microorganisms.

FIG. 3 differences in levels of gut microbiota in groups of mice.

FIG. 4 difference in the level of intestinal microbiota in mice of each group.

FIG. 5 differences in the level of gut microbiota in mice of each group.

FIG. 6 Change in duodenal goblet cells (magnification × 400) in each group of mice.

FIG. 7 change (. times.400) of jejunal goblet cells of each group of mice.

FIG. 8 change of ileal goblet cells (x 400) for each group of mice.

FIG. 9 variation in the number of goblet cells in each group of mice.

FIG. 10 expression of MUC-2 in duodenum of groups of mice (. times.400).

FIG. 11 shows the variation of the content of lysozyme and Trifolium factor in duodenale and Trifolium factor in each group of mice.

FIG. 12 variation of duodenal diglycosidase content in each group of mice.

FIG. 13 morphological changes in duodenal tissues (HE staining, X400) in groups of mice.

FIG. 14 morphological changes of jejunal tissue (HE staining, X400) in groups of mice.

FIG. 15 mouse ileum histomorphosis (HE staining, X400) for each group

FIG. 16 Small intestine Chiu's scores for each group of mice.

FIG. 17 Effect of intestinal tissue V/C ratio in groups of mice.

FIG. 18 change in duodenal ultrastructure (. times.8000) in each group of mice.

FIG. 19 change of jejunal ultrastructure (. times.8000) in each group of mice.

FIG. 20 change of ileum ultrastructure (. times.8000) in each group of mice.

FIG. 21 expression of the TJ-associated protein Occludin protein in duodenum of groups of mice.

FIG. 22 expression of the TJ-related protein Claudin-1 protein in duodenum of each group of mice.

FIG. 23 expression of TJ-related protein Zo-1 protein in duodenum of each group of mice.

FIG. 24 expression of the TJ-related protein JAMA protein in duodenum of each group of mice.

FIG. 25 expression of the TJ-associated protein MLCK protein in duodenum of each group of mice.

FIG. 26 changes in the levels of DAO, D-LA and ET in the sera of groups of mice.

FIG. 27 CD3 in peripheral blood lymphocytes of groups of mice⁺And CD19⁺A two-dimensional lattice of cells.

FIG. 28 CD3 in peripheral blood of mice in each group⁺T and CD19⁺Change in percentage of B.

FIG. 29 CD4 in peripheral blood lymphocytes of mice of each group⁺And CD8⁺A two-dimensional lattice of cells.

FIG. 30 CD4 in peripheral blood of mice in each group⁺、CD8⁺Percentage sum CD4⁺/CD8⁺A change in (c).

FIG. 31 TH in peripheral blood of mice in each group₁And TH₂CD4⁺A two-dimensional lattice of T lymphocytes.

FIG. 32 TH in peripheral blood of mice in each group₁And TH₂CD4⁺Change in percentage of T lymphocytes.

FIG. 33 variation of cytokine levels in duodenum of groups of mice.

FIG. 34 variation of immunoglobulin content in serum of each group of mice.

FIG. 35 variation of sIgA content in duodenum, jejunum and ileum of each group of mice.

Detailed Description

The invention is described in further detail below with reference to specific embodiments and with reference to the following figures:

example 1: traditional compound optimization screening experiment for Mongolian veterinary drug BBS

1.1 Experimental consumables and Equipment

1.1.1 Primary reagents

Common nutrient agar, eosin methylene blue nutrient agar, nutrient broth, ciprofloxacin (batch number: 11220023), purchased from Guangzhou Baiyunshan pharmaceutical GmbH; myrobalan, madder, black-leaved sweetberry, black-cloud incense, rhubarb, nardostachys chinensis, fringed pink and the like are purchased from inner Mongolia Tianli pharmaceutical industry Co.

1.1.2 strains

Pathogenic E.coli (E.coli O)₁) The bacterial strain is given by a ox production laboratory Aoge professor of the animal science institute of inner Mongolia university, and is separated, identified and stored by the Yangqi Boshi in the experiment team of the Aoge professor.

1.1.3 Experimental animals

SPF-grade Kunming mice, half male and female, with the weight of 23 +/-2 g, purchased from the experimental animal center of university of inner Mongolia, license number: SCXK (monte 2016-. Mice were placed in individually dry ventilated cages, 10 per cage, and after acclimation for 3 days, the experiment was started. The experimental mice were in compliance with the protocols approved by the animal protection use committee of the university of inner mongolia agriculture.

1.1.4 Main Instrument

Double-sided vertical air supply ultra-clean bench, biochemical incubator (HPS-250.SW-CJ-2D), Suzhou Borelair Equipment clean Inc.; ST-360 microplate reader, Jinan Hailaibao medical devices Limited.

1.2 Experimental methods

1.2.1 cultivation of the laboratory bacteria

Before use, the frozen strains are streaked on Macconk culture medium, eosin methylene blue culture medium and nutrient agar culture medium respectively, and cultured in a constant temperature incubator at 37 deg.C for 18h to obtain Escherichia coli pure culture, and the Escherichia coli pure culture is stored in a refrigerator at 4 deg.C, before test, the bacterial liquid is adjusted to 1.0 × 10 by McBthz method⁸cfu/ml。

1.2.2 extraction of drugs

Pulverizing different herbs with a pulverizer by adopting a water extraction method, sieving with a 40-mesh sieve, respectively taking 50g of different medicines, putting into a filtering medicine bag sewn by 8 layers of gauze, adding 10 times of distilled water, soaking overnight at room temperature, decocting with slow fire for 1h, filtering the liquid medicine with eight layers of gauze, adding 250mL of distilled water into filter residues again, decocting for 30min, filtering, combining the two filtrate, and concentrating with slow fire to 50mL (namely the crude drug content in the liquid medicine is 1 g/mL). Sterilizing at 121 deg.C under high pressure, and storing in refrigerator at 4 deg.C. 1.2.3 bacteriostatic diameter determination

Taking 100uL of bacterial liquid (1.0X 10) in a clean bench⁸cfu/mL) was uniformly spread on the surface of sterile agar, 3 sterile Oxford cups were placed in a triangular shape in a petri dish with a bacterial layer, 200uL of the liquid medicine was added to the Oxford cups, and the mixture was cultured in a constant temperature incubator at 37 ℃ for 18 hours. The diameter of the zone of inhibition was measured with a vernier caliper, and the results were averaged over 3 replicates. The judgment standard is that the negative represents that no inhibition zone is generated or the negative is not sensitive; the diameter R of the inhibition zone is more than or equal to 15mm, and the drug is extremely sensitive; the high sensitivity is that R is more than or equal to 10mm and less than or equal to 15mm, the low sensitivity is that R is more than or equal to 8mm and less than or equal to 10mm, and the low sensitivity is that R is less than or equal to 8 mm.

1.2.4 determination of MIC, MBC concentration

The assay was carried out by microdilution and plate methods. Taking a sterile 96-well plate, adding a liquid medicine diluted by 2 times of the broth into 1-8 holes (test holes), wherein 200uL of each hole is provided, 9 holes are used as positive control holes (without medicine) and 10 holes are used as negative control holes (without pathogenic bacteria). Adding 100uL of diluted 1.0 multiplied by 10 into 1-9 holes⁶cfu/mL bacterial liquid. After shaking and mixing uniformly, putting the mixture in a thermostat at 37 ℃ for culturing for 24h, and observing the culture result. If the turbidity in the holes is 1-8, the bacteria growth is the same as the positive control; if the clear in 1-8 holes, no bacteria grows, namely the same as the negative control group. Eye sightAnd (4) observing that no bacteria grow and the lowest concentration of the medicine is the lowest inhibitory concentration (MIC) of the Mongolian veterinary medicine to the strain. 100uL of the suspension was evenly spread on nutrient agar from each well where no growth occurred. Culturing at 37 ℃ overnight, wherein the lowest liquid medicine concentration of the colony count less than 5-10 is the Minimum Bactericidal Concentration (MBC). MIC is less than 7.80mg/mL, and the product is highly sensitive; MIC is more than or equal to 7.80mg/mL and less than or equal to 250mg/mL, and the sensor is moderate sensitive; MIC > 250mg/mL, was insensitive.

1.2.5 determination of FIC index

Coli O will be pathogenic₁The sensitive Mongolian veterinary drug is diluted by sterile broth 2 times into 10 gradients of 1000, 500, 250, 125, 62.5, 31.3, 15.6, 7.8, 3.9 and 1.95 mg/mL. And (3) designing the prepared Mongolian veterinary drug according to a chessboard method, and determining MIC. Results were observed and the synergy index (FIC) was calculated, which is MIC (combination a)/MIC (combination a) + MIC (combination b)/MIC (combination b). FIC index is less than or equal to 0.5, and synergistic effect is achieved; the FIC index is more than 0.5 and less than or equal to 1, and the data are accumulated; FIC index is more than or equal to 1 and less than or equal to 2, and is irrelevant; FIC index > 2, antagonistic action.

1.2.6 measurement of Minimum Lethality (MLD)

Coli O₁Transferring to 3 rd generation, diluting with sterilized normal saline solution by 10 times when the activity is optimal, and diluting to 1.0 × 10¹³CFU/mL、1.0×10¹²CFU/mL、1.0×10¹¹CFU/mL、1.0×10¹⁰CFU/mL and 1.0X 10⁹CFU/mL concentration gradient, 5 gradient bacterial suspensions were injected into 10 mice, and sterile normal saline negative control group was set. Coli O to determine pathogenicity₁100% MLD concentration for mice. The death status in mice 3d was observed and the results were recorded. The grouping and injection protocol is shown in table 1.

Table 1 pathogenicity e₁100% MLD mouse intraperitoneal injection scheme

Table.1 Injection regimen of pathogenic E.coli O₁to mice for 100％MLD

1.2.780% MLD assay

As is clear from the results in Table 1, 0.3mL of 1.0X 10 was injected into the abdominal cavity¹¹CFU/mL E.coli O₁All mice died, while mice below this concentration did not show all deaths. Therefore, will be 1.0 × 10¹¹E.coli O of CFU/mL₁The mice were diluted 2-fold and given intraperitoneal injections after five gradients in the storage mice that passed the adaptation phase. Observing the death status of the mice in 3d and determining the pathogenicity E₁80% MLD concentration to mice. The grouping and injection protocol is shown in table 2.

Table 2 pathogenicity e₁80% MLD mouse intraperitoneal injection scheme

Table.2 Injection regimen of pathogenic E.coli O₁to mice for 80％MLD

1.2.8 Mongolian veterinary drug BBS compound single-ingredient Mongolian veterinary drug for inhibiting pathogenicity E₁Dose optimization

Healthy mice were randomly grouped into groups of 10 mice/group, each half of male and female, according to L₁₈(3⁷) Orthogonal design (see table 3) was divided into 18 groups, while negative control group (distilled water) and positive control group (ciprofloxacin) were set. The pharmaceutical factors and their dose level settings are shown in table 3, the experimental group dosing regimen is shown in table 4, and the continuous dosing is 7d, 2 times/d. Mice were injected intraperitoneally 2h after the last dose with 80% MLD pathogenic e₁0.3mL of the antibacterial agent is injected into each mouse, the death number of the mouse within 2d is observed, and the antibacterial protection rate is calculated. The results were counted using range analysis. The protection rate was (1-test group death/negative control group death) × 100%.

TABLE 3L₁₈(3⁷) Orthogonal table

Table 3 L₁₈(3⁷)orthogonal table

TABLE 4 BBS Compound recipe formulation factor dose level design (g)

Table 4 Design of main factors dosage level of orthogonal compound Mongolian medicine BBS

1.2.9 Mongolian veterinary drug BBS compound for E.coli O infection₁Determination of in vivo antibacterial protection ratio of laboratory mice

Healthy mice were randomly divided into 5 groups, 10 mice/group, and male and female halves, which were respectively a negative control group (distilled water), a positive control group (ciprofloxacin), and a BBS complex group. The experimental groups and dosing schedule are shown in Table 5, with 7d, 2 times/d of consecutive doses. Mice were injected intraperitoneally 2h after the last dose with 80% MLD pathogenic e₁In addition, 0.3mL of the antibacterial agent is injected into each mouse, the death number of the mouse within 2d is observed, and the antibacterial protection rate is calculated. The antibacterial protection rate is (1-test group death/negative control group death) × 100%.

TABLE 5 Experimental groups and dosing regimens for antibacterial protection rates in mice

Table.5 The experimental grouping and the administration regimen of antibacterial protection rate in mice

1.3 Experimental results and analysis

1.3.1 Each single herb in the Compound recipe is responsible for pathogenicity E₁Determination of in vitro bacteriostatic effects

As can be seen from Table 6, Mongolian medicineIn the experiment of in vitro antibacterial zone of veterinary drug, radix Aconiti Kusnezoffii, fructus Chebulae, herba Blumeae Laciniatae, and radix et rhizoma Rhei have pathogenicity to E₁The bacteriostatic diameter of the antibacterial agent is between 10.19 and 13.26mm, and R is more than or equal to 10 and less than 15mm, so that the pathogenicity E₁Has high sensitivity to 4 Mongolian veterinary drugs such as radix Linderae, fructus Chebulae, herba Blumeae Laciniatae, radix et rhizoma Rhei, etc. Pathogenic E coli O caused by Oxytropis myriophylla, Rubia cordifolia and Nardostachys chinensis₁The bacteriostatic diameter of the antibacterial agent is 9.20-9.87 mm, and R is more than or equal to 8 and less than 10mm, so that the pathogenicity E₁The compound has low allergy to the 3-flavor Mongolian veterinary drugs such as Oxytropis myriophylla, madder and Nardostachys chinensis. In the in-vitro MIC and MBC bacteriostatic experiments of Mongolian veterinary drugs, the myrobalan fruit has pathogenicity of E₁The bacteriostatic effect is shown to be highly sensitive, the MIC is 0.063g/mL, and the MBC is 0.125 g/mL; caulis et folium Linderae Caudatae, herba Blumeae Laciniatae, radix et rhizoma Rhei, Oxytropis myriophylla, radix Rubiae, and rhizoma Nardostachyos to pathogenicity E₁The bacteriostatic effect is moderate sensitivity, the MIC is 0.125-0.25 g/mL, and the MBC is 0.125-0.5 g/mL.

Table 6 pathogenic e.coli O of each single Mongolian veterinary drug in the compound formulation₁Determination of in vitro bacteriostatic diameter, MIC and MBC

Table 6 Diameter of inhibition zone，MIC and MBC of each single Mongolian medicine of compound against pathogenic E.coli O₁in vitro

Injecting; the diameter R of the inhibition zone is more than or equal to 15mm, and the drug is extremely sensitive; r is more than or equal to 10 and less than 15mm, and the high sensitivity is realized; r is more than or equal to 8 and less than 10mm, and low sensitivity is achieved; r < 8mm is insensitive. MIC is less than 0.0780g/mL, and the product is highly sensitive; MIC is more than or equal to 0.0780g/mL and less than or equal to 0.25g/mL, and the product is moderate sensitive; MIC > 0.25g/mL, was not sensitive.

Note：Inhibition zone，R≥15mm is significantly sensitive，10≤R＜15mm is highly sensitive，8≤R＜10mm is low sensitive，R＜8mm is no sensitive.MIC＜0.0780g/mL，is significantly sensitive，0.0780g/mL≤MIC≤0.25g/mL，is highly sensitive，MIC＞0.25g/mL，is no sensitive.

1.3.2 pathogenic E₁Determination of 100% MLD

As shown in Table 7, 0.3mL of 1.0X 10 was injected into the abdominal cavity¹³～1.0×10¹¹Coli O of CFU/mL₁The mortality rate is 100%; intraperitoneal injection of 0.3mL and 1.0X 10¹⁰Coli O of CFU/mL₁The mortality rate is 50%; intraperitoneal injection of 0.3mL and 1.0X 10⁹Coli O of CFU/mL₁The mortality rate was 30%. The minimum bacteria concentration with 100% fatality rate, namely 1.0X 10 is adopted¹¹CFU/mL was used as the starting concentration for screening 80% MLD for the next experiment.

Table 7 pathogenicity e₁Measurement results of 100% MLD

Table.7 The results of pathogenicE.coli O₁of 100％MLD

1.3.3 pathogenic E₁Determination of 80% MLD

As shown in Table 8, the mouse was injected with 0.3mL of 1.0X 10 solution into the abdominal cavity¹¹～0.5×10¹⁰Coli O of CFU/tnL₁The mortality rate is 100%; mouse intraperitoneal injection of 0.3mL and 2.5X 10¹⁰Coli O of CFU/mL₁The mortality rate is 90%; mouse intraperitoneal injection of 0.3mL and 1.25X 10¹⁰Coli O of CFU/mL₁The mortality rate was 80%. Mouse intraperitoneal injection of 0.3mL and 6.25X 10⁹Coli O of CFU/mL₁The mortality rate was 60%. Therefore, pathogenic e₁80% MLD is 1.25X 10¹⁰CFU/mL。

Table 8 pathogenicity e₁Measurement result of 80% MLD

Table.8 The results of pathogenic E.coli O₁of 80％MLD

1.3.4 Each single herb in BBS compound of Mongolian veterinary drug inhibits pathogenicity E₁Dose optimization of

As can be seen from Table 9, according to L₁₈(3⁷) Orthogonal table design experiment proves that different dosages of Mongolian veterinary drug are used for verifying pathogenicity of E₁The antibacterial protection rate of the composition. The optimum ratio of each single Mongolian veterinary drug in the BBS compound of the Mongolian veterinary drug can be obtained by adopting a range analysis method, wherein the ratio of A to B to C to D to E to F to G is 3: 2: 3.

TABLE 9 determination result of antibacterial protection rate of Mongolian veterinary drug BBS compound on mice

Table.9 The determination results of BBS Mongolian compound to antibacterial protection in mice

1.3.5 Mongolian veterinary drug BBS (BBS Compound for treating E.coli O. infection)₁Determination of in vivo antibacterial protection ratio of laboratory mice

As can be seen from table 10, antibiotic ciprofloxacin is pathogenic for infection e₁The protection rate of the mice is 75 percent; mongolian veterinary drug BBS compound for E₁The protection rate of the mice was 62.5%.

Table 10 Mongolian veterinary drug BBS Compound on infection E₁In vivo antibacterial protection rate of mice

Table 10 Protection rate of compound BBS Mongolian medicines to mice infected with E.coli O₁

1.4 conclusion:

1. the Mongolian veterinary medicine babu-7 compound is as follows: 5g of radix aconiti kusnezoffii, 2.5g of myrobalan, 2.5g of oxytropis leafmulberry, 2.5g of madder, 2.5g of black sesame, 5g of nardostachys root and rhizome, and 5g of rhubarb

2. The antibacterial protection rate of the Mongolian veterinary drug babu-7 compound on mice is 62.5%.

Example 2: clinical cure experiment of Mongolian veterinary drug BBS on calf with colibacillosis diarrhea

2.1 materials of the experiment

2.1.1 test animals

Selecting 48 Holstein calves with similar body weight (40 +/-2 kg). The groups were randomly divided into 6 groups of 8 heads each.

2.1.2 test drugs

The 7 Mongolian medicines are crushed by a crusher, sieved by a 200-mesh sieve, and are mixed according to the preparation dosage, and are purchased from inner Mongolian Tianli pharmaceutical industry Co. The ciprofloxacin group (production batch: 20180316) was purchased from Youth Xinheng pharmaceutical Co., Ltd.

2.2 test methods

2.2.1 test design

The test was conducted in the inner Mongolia Ordosdale Knight pasture and was approved by the owner of the company. All experimental protocols were approved by the institutional animal care committee of the university of inner mongolia agriculture and were conducted according to the guidelines of the animal ethics committee of the institute of veterinary medicine of the university of inner mongolia agriculture. The calf is fed with 4L milk at 1 week old per day by mixing the test medicines with milk at ratio of 6: 30 and 18: 30.

Selecting 48 healthy Holstein calves with similar body weights (40 +/-2 kg), randomly dividing into 6 groups of 8 calves in each group, and respectively selecting a normal control group (VG) and a model group (MG + E₁) Ciprofloxacin group (0.5mg/kg. b.w. CG + E₁) Mongolian medicine babu-7 compound low-dose group (2.50g/kg. b. w BBS-L + E. coli O. Coli O₁) Babu-7 medium dose group (5.0g/kg. b. w BBS-M + E. coli O₁) Babu-7 high dose group (10.0g/kg. b. w BBS-H + E. coli O₁) See table 11. Oral inoculation of pathogenic e₁(2.50×10¹¹CFU/mL, 100 mL/head) to establish diarrhea model, after the diarrhea model is successful, continuously treating for 7d, 2 times/d (each test drug is mixed in milk for administration), and sampling in 8d morningAnd counting the results.

TABLE 11 Calf test grouping and dosing regimen

Table 11 Schematic overview of concerning and dosage regimens

2.2.2 Calf clinical symptoms at test period, record of diarrhea

Observing calf mental state, hair luster degree, activity, appetite, food intake, etc. during the test period; calf feces scoring data is collected, wherein the feces scoring is shown in table 12, and diarrhea is evaluated by more than 2 points. Recording the body weight before and after the calf test.

TABLE 12 stool score table

Recording the excrement condition of each calf every day according to a criterion, and calculating according to a formula:

diarrhea Rate (Diarrhea Rate, DR) -Diarrhea head/total head X100%

2.2.3 data statistics and analysis

Analysis was performed using SPSS 17.0 statistical software (SPSS, inc., Chicago, IL, USA) expressed as mean ± standard deviation. Differences between groups were determined by One-way analysis of variance (ANOVA) and significance of differences between groups (p < 0.05 and p < 0.01) was determined by One-way analysis of variance (One-way ANOVA).

2.3 results and analysis

2.3.1 Effect of Mongolian medicine babu-7 on Calf body weight

As can be seen from Table 13, before the test, the differences between the groups of the weights of the calves at birth were not significant (P > 0.05). After 7d administration, the MG group weight was significantly reduced compared to VG (P < 0.05). Compared with MG, the BBS treatment group has slightly increased body weight, but has no significant difference, and is equal to CG (P is more than 0.05). Compared with VG, the body weight difference of BBS treatment groups is not significant, and the fact that the Mongolian veterinary drug BBS can regulate and control the body weight of calves to be normal (P is more than 0.05) is proved.

TABLE 13 Effect of Mongolian medicine babu-7 on weight gain in diarrheal calves

Table 13 The effect of Mongolian medicine Babu-7 on weight gain of diarrhea calves

2.3.2 Effect of Mongolian veterinary drug babu-7 on Calf diarrhea Rate

The effect of the Mongolian drug babu-7 on the diarrhea rate and mortality of the diarrhea model calves is shown in Table 14. After 7 days of administration, the MG diarrhea rate reached 87.5%. The diarrhea rate of BBS-M, BBS-H, CG is 25 percent, and the cure rate is 75 percent. Compared with VG, the calf diarrhea rate of BBS-M, BBS-H, CG group is increased. Furthermore, no calf death occurred in each group during the trial.

TABLE 14 Effect of Mongolian veterinary drug babu-7 on diarrhea Calf diarrhea Rate

Table 14 Effect of Mongolian medicine Babu-7 on diarrhea rate in diarrhea calves

2.4 conclusion:

the Mongolian veterinary drug babu-7 can reduce the diarrhea rate of calves and increase the weight, wherein the effect is the best at 10.0 g/kg.b.w.

Example 3 Effect of Mongolian veterinary drug BBS Compound on intestinal mucosal biological Barrier of mice with colibacillosis diarrhea

3.1 Experimental materials

3.1.1 bacteria for experiments

Pathogenic E.coli (E.coli O)₁) Presented by ox production laboratory Aorigle professor at animal science institute of inner Mongolia university, separated, identified and stored by the Yanste Boshi.

3.1.2 Experimental animals

SPF-grade Kunming mice, half male and female, with the weight of 23 +/-2 g, purchased from the experimental animal center of university of inner Mongolia, license number: SCXK (monte 2016-. In independent drying ventilation cages, 10 cages are respectively filled with constant temperature (21 +/-2 ℃), constant humidity (53 +/-5%), free food and drinking water, and the light/dark cycle is 12 h. Is suitable for breeding for 3d and experiments are developed. The experiment was in compliance with the protocols approved by the animal protection use committee of the university of inner mongolia agriculture.

3.2 Experimental methods

3.2.1 preparation of the drug

The preparation method comprises the following steps of mixing the single herbal medicines according to a formula of a babu-7 compound, crushing the mixture by using a crusher, sieving the mixture by using a 40-mesh sieve, putting the medicines into a filtering bag sewn by 8 layers of gauze, adding 10 times of distilled water, soaking the medicines at room temperature overnight, decocting the medicines with slow fire for 1 hour, filtering the liquid medicine by using eight layers of gauze, adding 250mL of distilled water into filter residues again, decocting the filter residues for 30min, filtering the decoction, combining the filtrate obtained in two times, and concentrating the filtrate with slow fire to 50mL (namely the crude drug content in the liquid medicine is 1 g/mL). Sterilizing at 121 deg.C under high pressure, and storing in refrigerator at 4 deg.C.

3.2.2 test bacterium culture

Inoculating pathogenic E.coli O1 in broth, culturing at 37 deg.C to logarithmic phase of 18-24 h, and adjusting mixed indicator bacteria to 1 × 10⁹After cfu/mL, the sample was placed in a refrigerator at 4 ℃ for further use.

3.2.3 diarrhea model establishment

2% sodium bicarbonate solution and 1.0X 10 by continuous 3d drench⁹CFU/mL pathogenicity e.coli O1 to establish a model of diarrhea in mice. And comprehensively evaluating the success of the diarrhea model according to clinical symptoms, autopsy symptoms, DAI scores, Chiu's scores of intestinal tissues, contents of intestinal inflammatory factors (TNF-alpha, MPO, IL-6 and IL-1 beta) and diarrhea rate. When mice are listened, crouched into lumps, thinned, secretion around eyes is increased, perianal area is polluted by loose excrement, hair on the back is tree, intestinal appearance is reddish when in autopsy, intestinal texture is thin and easy to break, intestinal tympanites, DAI score is more than 6, content of inflammatory factors in intestinal tract is increased, intestinal villi is broken and disintegrated, inflammatory cells are infiltrated, diarrhea rate reaches 75%, and diarrhea symptom can last for more than 72h, namely molding success is achieved.

3.2.4 Experimental groups and dosing regimens

After a mouse escherichia coli diarrhea model is successfully established, a Mongolian veterinary drug BBS compound is used for treatment. 85 Kunming mice, 10 per group, were randomly divided into 6 groups, and the experimental groups and dosing schedule are shown in Table 15. After successful modeling, treatment was continued for 7 days, and surviving mice (approximately 10 in each group) were sacrificed on the 8 th morning and samples were collected for subsequent experimental analysis.

TABLE 15 Experimental groupings and dosing schedules

Table.15 The trial grouping and dosage regiment

3.2.4 DNA extraction

Microbial DNA was extracted from the collected cecal content samples according to the QIAamp Fast DNA pool Mini-Kit instructions. For each sample, total DNA concentration and integrity were quantified using uv spectrophotometer at wavelengths of 260 and 280nm and 1.0% agarose gel electrophoresis, and the extracted qualified nucleic acids were immediately stored at-80 ℃ for further analysis.

3.2.516S rRNA Gene amplification

The V3-V4 region of bacterial 16S ribosomal RNA (rRNA) was amplified by PCR. Primer: 341F (5 '-CCTAYGGGRBGCASCAG-3'), 805R (5 '-GGACTACNNGGGTATCTAAT-3'). Reaction conditions are as follows: pre-denaturation (95 ℃, 3min), denaturation (95 ℃, 30s, 25 cycles), annealing (55 ℃, 30s), extension (72 ℃, 45s), terminal extension (72 ℃, 10min), stop (10 ℃). The PCR reaction was referenced to 50. mu.L, containing 5. mu.L of LTaq polymerase, 10 ng/. mu.L (5. mu.L) of template DNA, and 1. mu.L each of 10. mu. mol/L of upstream and downstream primers. PCR products were recovered and purified using AxyPrep DNA gel extraction kit instructions.

3.2.6 library construction and sequencing

And constructing a Library of 2 mu g of the purified PCR product by using an Ion Plus Fragment Library Kit 48rxns Library construction Kit, quantifying the Qubit and detecting the Library to be qualified, and performing on-machine sequencing by using Ion S5 TMXL.

3.2.7 sequencing data processing

According to the Barcode sequence and the PCR amplification primer sequence, each sample sequence is obtained from the primer sequence, after the Barcode and the primer sequence are cut off, reads of each sample are spliced by Cutadaptt (V1.9.1, http:// cutadat. The Raw Reads sequence was aligned by stringent filtering (https:// github. com/torogens/vsearch /) and the final valid data was obtained after removal of the chimeric sequence (clear Reads).

3.2.8 OTU clustering and species annotation

Firstly, clustering operation units (OTUs) are cut off by 97% of similarity through Uperase software (version 7.0.1001 http:// www.drive5.com/Uparse /), and high-frequency occurrence sequences are selected as representative sequences of OUT. Species annotation analysis (threshold 0.8-1) was then performed on the OTU sequences using the Mothur method with the SSUrRNA database of SILVA132 (http:// www.arb-SILVA. de /). Reuse MUSCLE (Version 3.8.31)http：//www.drive5.com/multiscale /) software to obtain phylogenetic relationships of all OTUS sequences.

3.2.9 sample complexity analysis (Alpha Diversity)

OTUs with a similarity of 97% were analyzed with Qiime software (Version 1.9.1) to calculate bacterial colony abundance and alpha diversity indices, including the observer-OTUs, Ace, Chao1, Ace, Shannon, Simpson, Goods-coverage, PD white tree indices. The dilution curve, the Rank abundance curve, and the species accumulation curve were plotted using R software (Version 2.15.3).

3.2.10 multiple sample comparison analysis (Beta Diversity)

OTUs with the similarity reaching 97% are analyzed by Qiime software (Version 1.7.0), and the Uniftac distance is calculated to construct a UPGMA sample clustering tree. Plots of PCA, PCoA and NMDS were made using R software (Version 2.15.3). LEfSe analysis was performed using LEfSe software, setting LDA Score screening value to 4 by default.

3.3 data statistics are the same as 1.3.

3.4 results of the experiment

3.4.1 species diversity curves and species cumulative boxplot results

The dilution curve is constructed by randomly extracting a certain amount of sequencing data from a sample, counting the number of species represented by them, i.e., (the number of OTUs), and plotting the extracted amount of sequencing data against the corresponding number of species. The dilution curve can directly reflect the rationality of sequencing data volume and indirectly reflect the abundance degree of species in a sample, when the curve tends to be flat, the sequencing data volume is gradually reasonable, and more data volume only can generate a small amount of new species. As shown in FIG. 1-a, the dilution curve of each sample tends to be flat, indicating that the sequencing quantity reaches the standard and the sequencing depth can cover all species in each sample. The grade clustering curve is drawn by using the sequencing number of the OTUs as an abscissa and using the relative percentage content of the sequence number in the grade OTU as an ordinate, and can visually reflect the richness and uniformity of species in a sample. The span of the curve on the abscissa is positively correlated with the abundance of the species, and the smoothness on the ordinate is positively correlated with the uniformity of the species. As shown in FIG. 1-b, the curve of each sample is smooth to show that the species are uniformly distributed. Species accumulation boxplot (species accumulation boxplot) is an analysis that describes the increase in species diversity as the sample size increases. Within a certain range, along with the increase of the sample size, if the position of the box diagram shows a sharp rise, the situation that a large number of species are found in the community is shown; when the boxplot position is flat, it means that the species in the environment does not increase significantly with the increase of the sample size. The species accumulation box chart can be used for judging whether the sample volume is sufficient or not, and the position of the box chart rises rapidly to indicate that the sample volume is insufficient and the sample volume needs to be increased; the box plot positions tend to be flat, indicating that sampling is sufficient and that data analysis can be performed. As shown in fig. 1-c, the box plot positions tend to be flat, indicating that the sample size of the study is sufficient and that the experimental data can be subsequently analyzed.

3.4.2 Alpha Diversity index analysis results

Alpha Diversity is used to analyze the abundance and Diversity of microbial communities Within a sample (Within a Within-community) [189 ]. The Shannon index and the Simpon index are two indexes reflecting the flora diversity, and the higher the Shannon index is, the higher the flora diversity is; otherwise, it is low. As can be seen from Table 16, the significant or very significant decrease in MG and CG Shannon indices (P < 0.05 or P < 0.01) compared to VG indicates a decrease in MG and CG microbiota diversity. Compared with MG, Shannon index of Mongolian veterinary drug babu-7 treatment group is obviously increased, which indicates that flora diversity of Mongolian veterinary drug babu-7 treatment group is increased. The simcon index is opposite to Shannon index, the higher the simcon index, the lower the flora diversity; otherwise, the higher. As can be seen from Table 16, the MG and CG Simpon indices were significantly or very significantly lower than those of the VG, BBS treatment groups (P < 0.05 or P < 0.01). The Chao1 index and the ACE index are two indexes reflecting the abundance of flora, and the algorithms are different, and the contents are the same. The Chao1 index and the ACE index are high, the flora abundance is increased, and conversely, the flora abundance is reduced. As can be seen from table 16, the Chao1 index and ACE index of VG and montmorial veterinary BBS treatment group were significantly higher than MG and CG. The Mongolian veterinary drug BBS treatment group flora is richer than MG and CG (P < 0.05 or P < 0.01) and is equivalent to VG. The underserved fields index and the Goods coverage index are sequencing depth indexes, the sequencing depth reaches 98-99%, and the sequencing depth completely covers the possible species in the sample.

TABLE 16 microbial population diversity index

Tab.16 Bacterial diversity index

3.4.3 multiple sample comparative analysis results (Beta Diversity)

Beta Diversity is a comparative analysis of the microbial community composition of different samples. As analytical methods, multivariate statistical methods such as Principal Component Analysis (PCA), Principal coordinate Analysis (PCoA), Non-Metric Multi-Dimensional Scaling (NMDS), Non-weighted group mean clustering (UPGMA), Unweighted Pair-group Method with iterative methods are commonly used. And (3) performing principal component analysis (PCoA) and UPGMA analysis by using R software based on the distance of the Bray-Curtis algorithm, and exploring the difference and similarity of flora structures among the groups of samples. UPGMA analysis results are shown in figure 2-a, main component analysis results are shown in figure 2-b, MG and antibiotics are distinguished and independently distributed with caecal microbial flora of mice in a normal group and a drug treatment group, and therefore mouse modeling and antibiotic treatment can obviously change the intestinal flora structure. While the VG and BBS treatment groups are not obviously and independently distributed, and part of the areas are overlapped, which shows that the BBS treatment can recover the flora disorder caused by modeling and is similar to the intestinal flora of VG mice.

3.4.4 Gate horizontal analysis results

In order to explore the difference of the dominant microflora of the cecal microorganisms of each group of mice, the top 10 ranked species at the level of the cecal microflora of each group of mice are selected for analysis, and the relative abundance of the different species is shown in figure 3. As can be seen from fig. 3, the relative abundance of Bacteroidetes (Bacteroidetes) and Verrucomicrobia (Verrucomicrobia) was significantly decreased in MG compared to VG (P < 0.05), and both bacteroides and Verrucomicrobia were significantly increased in cecal microorganisms of other groups of mice compared to MG. The relative abundance of Proteobacteria (Proteobacteria) and Firmicutes (Firmicutes) was significantly increased for MG compared to VG (P < 0.05). The relative abundance of Proteobacteria and firmicutes in CG, BBS-H, BBS-M group mouse cecal microorganisms was significantly reduced compared to MG (P < 0.05).

3.4.5 mesh level analysis results

In order to explore the difference of the dominant flora of the cecal microorganisms of each group of mice, the top 10 ranked species of the cecal microorganisms of each group of mice at the target level are selected for analysis, and the relative abundance of the different species is shown in figure 4. As can be seen from FIG. 4, MG has a significant increase (P < 0.05) in Clostridiales (Clostridium) and Enterobacteriales (Enterobacteriales) compared with VG, and has a significant decrease (P < 0.05) in CG, BBS-H, BBS-M groups of Clostridiales and Enterobacteriales compared with MG. The relative abundance of Bacteroides (Bacteroides), Lactobacillales (Lactobacillales) and Verrucomicrobiales (Verrucomicrobiales) was significantly reduced in MG compared to VG (P < 0.05), and in CG, BBS-H group mice cecal microorganisms, Bacteroides, Lactobacillales and Verrucomicrobiales were significantly increased in CG, BBS-H group mice compared to MG (P < 0.05).

3.4.6 genus level analysis results

In order to explore the difference of the dominant flora of the cecal microorganisms of each group of mice, the top 10 ranked species on the cecal microorganism genus level of each group of mice are selected for analysis, and the relative abundance of the different species is shown in figure 5. As seen in FIG. 5, the presence of MG in Enterococcus (Enterococcus) and Clostridium in Clostridium was significantly increased (P < 0.05) as compared with VG. The BBS-treated group significantly reduced the relative abundance of Enterococcus (Enterococcus) and Clostridium (P < 0.05) compared to MG. Compared with VG, the relative abundance of Bacteroides and Lactobacillus of the BBS treatment group is remarkably increased (P < 0.05) compared with MG.

3.5 conclusion: the Mongolian veterinary drug BBS compound can improve the reduction of the richness and diversity of floras caused by pathogenic escherichia coli by increasing the quantity of beneficial bacteria and reducing the quantity of harmful bacteria.

Example 4 Effect of Mongolian veterinary drug BBS Compound on intestinal mucosal chemical barrier of mice with colibacillosis diarrhea

4.1.1 test and consumables

Fluorescent (CY3) labeled goat anti-rabbit IgG (manufacturing lot: BA1032), blocking concentrated normal goat serum (manufacturing lot: BA1032), purchased from Dr. Wuhan bioengineering, Inc.; muc-2 (production lot: A14659), Abclone; DAPI (production lot: C1002), available from Binyun corporation; the anti-fluorescence quenching encapsulated tablet (production batch number: 0100-01), southern biotech, ITF, lysozyme and ELISA kit are all purchased from Wuhan enzyme immunoassay biotechnology limited; lactase detection kit, sucrase detection kit and maltase detection kit are all purchased from Nanjing constructed reagent Co.

4.1.2 the same strain as 3.1.2.

4.1.3 Experimental animals were the same as 3.1.3.

4.1.4 the main apparatus is as 3.1.4.

4.2.1 preparation of traditional compound BBS for Mongolian veterinary drug is the same as 3.2.1.

4.2.2 test strains were cultured as in 3.2.2.

4.2.3 experimental groups and dosing regimens were as in 3.2.3.

4.2.4 PAS dyeing

Embedding tissue by conventional method, slicing, dewaxing tissue slice by conventional method, dehydrating, soaking slice with 1% periodic acid water solution for 10min, and washing with distilled water for 2 min; adding Schiff's reagent dropwise onto the sliced tissue, incubating at room temperature in dark place for 20min, and washing the slices with running water for 5min 2 times; carrying out Mayer hematoxylin counterstaining for 2min, and washing with tap water until cell nuclei turn blue; dehydrating with anhydrous ethanol, air drying in fume hood, sealing with neutral gum, and examining under microscope; and (4) taking pictures by 400-fold optical microscope, randomly selecting 5 fields for each section, counting the goblet cells in every 100 cells in the fields, and taking an average value.

4.2.5 immunofluorescence the immunofluorescence experiments were performed using the general methods. The MUC-2 dilution ratio is 1: 100.

4.2.6 ELISA

100mg of fresh ileum tissue is put into an electric tissue homogenizer, 0.9mL of sterilized normal saline is added to prepare tissue homogenate, 3000r/min is carried out, and supernatant is taken after centrifugation for 10 min. Intestinal trefoil factors (lysozyme, ITF-3, and disaccharide enzyme activity) were detected according to the kit instructions.

4.3 data processing is the same as 1.3.

4.4 results and analysis

4.4.1 intestinal tissue goblet cell assay results

As shown in FIGS. 6-8, the staining of PAS showed that the VG mouse intestinal mucosal goblet cells are circular or elliptical and are distributed mostly in the middle and basal part of the intestinal villus. MG mouse intestinal mucosa goblet cell body type diminishes, color is lighter, quantity obviously reduces, disperses in the middle and upper part of intestinal villus, intestinal gland, villus basal portion distribute less. Compared with MG mice, the number of CG and BBS-H group goblet cells is obviously increased, the body size is slightly larger, and the coloration is clear. The distribution of the shape of the goblet cells of the hollow and ileum has similar trend.

As can be seen from fig. 9, in the duodenal goblet cells, MG was significantly reduced compared to VG (P < 0.01); compared with MG, CG and BBS-H, BBS-M are both increased significantly or extremely significantly (P < 0.01 or P < 0.05). The empty and ileal goblet cells have similar trends and numbers vary from small to large from the duodenum to the ileum.

4.4.2 detection results of MUC-2

As can be seen from FIG. 10, the fluorescence intensity of MUC-2 in duodenum of MG mice was significantly weaker than that of VG (p < 0.05), and each group was significantly stronger than MG (p < 0.05) outside of BBS-L group.

4.4.3 detection results of Lysozyme and ITF

As can be seen from FIG. 11, the lysozyme activity in duodenum of MG mice is significantly lower than that of VG (P < 0.001); the mice in each treatment group are remarkably or extremely remarkably higher than MG (P < 0.01 or P < 0.05), and BBS-H effect is optimal. Intestinal trefoil factor, significantly lower than VG in the duodenum of MG mice (P < 0.001); each treatment group is significantly or very significantly higher than MG (P < 0.01 or P < 0.05), and BBS-H has the best effect (P < 0.001).

4.4.4 detection results of the Activity of the disaccharide enzyme

As can be seen from FIG. 12, the activity of maltase in duodenum of MG mice is significantly lower than that of VG (P < 0.001); each treatment group is significantly or extremely significantly higher than MG (P < 0.01 or P < 0.05), and BBS-H has optimal effect. Lactase activity in duodenum of MG mice is significantly lower than VG (P < 0.001); each treatment group is significantly or extremely significantly higher than MG (P < 0.01 or P < 0.05), and BBS-H element has optimal effect (P < 0.001). As can be seen from FIG. 14-c, sucrase activity in duodenum of MG mice was significantly lower than that of VG (P < 0.001); except BBS-L, each treatment group is significantly or very significantly higher than MG (P < 0.01 or P < 0.05), and BBS-H has the best effect (P < 0.001).

4.5 conclusion

The Mongolian veterinary BBS compound can increase the number of goblet cells and mucin MUC-2 secreted by the goblet cells, improve the activity of lysozyme, the activity of diglycosidase and the content of TFF3, enhance the adhesion to pathogenic bacteria and prevent pathogenicity E₁Thereby alleviating the symptoms of diarrhea.

Example 5 Effect of Mongolian veterinary drug BBS Compound on intestinal mucosal mechanical Barrier of mice with colibacillosis diarrhea

5.1.1 reagents and consumables

The medicinal materials are as above; occludin (batch: Ab216327), Claudin-1 (batch: Ab15098), Zo-1 (batch: 21773-1-ap), MLCK (batch: Ab76092), JAM-A (batch: Ab180821), purchased from Abeam; DAO, D-LA and ET ELISA kits were purchased from Wuhan enzyme immunoassay Biotech, Inc.

5.1.2 the experimental strain was the same as 3.1.2.

5.1.3 Experimental animals were the same as 3.1.3.

5.2.1 preparation of the medicament is the same as 3.2.1.

5.2.2 test strains were cultured as in 3.2.1

5.2.3 the experimental groups and dosing schedule were as for 3.2.3.

5.2.4 Experimental procedures and sample Collection

Injecting 1% sodium pentobarbital into the abdominal cavity of a mouse according to 50mg/kg bw for anesthesia, collecting 1mL of blood from the heart, standing at room temperature for 60min, centrifuging at 3000r/min for 15min, and collecting serum for subsequent experiments of detecting inflammatory factors, intestinal mucosa permeability and the like. Aseptically, 1cm of duodenum was taken 0.5cm away from pyloric sphincter, 1cm of jejunum was taken 0.5cm away from Merkel diverticulum, and 1cm of ileum was taken 0.5cm away from ileocecal hole, and washed with ice physiological saline. The intestinal tissue specimen is divided into three parts, and the tissue size is 1.5 multiplied by 1mm³. Two portions were fixed to 2.5% glutaraldehyde (pH 7.4, 4 ℃) for HE, immunohistochemistry and intestinal epithelial cell microstructure observation; one part of the protein is quickly placed in a DEPC (diethyl phthalate) processing low-temperature test tube, stays overnight in liquid nitrogen, is stored in a refrigerator at minus 80 ℃ and is prepared for researching the relative expression levels of genes and proteins of Ocplus, Claudin-1, ZO-1, JAMA and MLCK.

5.2.5 HE staining

HE conventional dyeing method. The longest and straightest intestinal villi of 5 pieces of each section were selected, the intestinal villi length (V), crypt depth (C) were measured with a micrometer, and the villi gland ratio (V/C value) was recorded and calculated. Scoring was performed according to the chiu's scoring criteria, which are shown in Table 17.

TABLE 17 qPCR reaction procedure

Table.17 The procedure of fluorescence quantitative PCR reaction

5.2.6 Transmission Electron microscopy. Observing and collecting images by an electron microscope.

5.2.7 immunohistochemical detection

The detailed steps of the pathological tissue section are the same as 2.2.3, and the immunohistochemistry is carried out according to the conventional steps.

5.2.8 RT-PCR

The procedure is as in 1.2.3, the primer list is shown in Table 18.

TABLE 18 primer sequences for tight junction related proteins

Table.18 Table of primers for tightly junction linked proteins

5.2.9 Western bolt：

Western bolt detection was performed according to the general procedure

5.2.10 ELISA:

and detecting the content of DAO, D-LA and ET in the serum of the mouse according to the instruction of the kit.

5.3 results of the experiment

5.3.1 Effect on pathological injury of intestinal tract of mice with colibacillosis diarrhea

From FIGS. 13-15, VG mice were found to have normal duodenal tissue structures. The MG mouse has obvious damage to the duodenal mucosa, disintegrated and broken intestinal villi, infiltration of a large number of inflammatory cells and ulcer. The symptoms of duodenum of BBS-H and CG mice are reduced, no obvious intestinal necrosis and hemorrhage are seen, intestinal villi are orderly arranged, but CG is slightly damaged. In the BBS-M group of mice, the duodenal villi is disintegrated, broken and infiltrated by inflammatory cells, but the complete intestinal villi form is still visible. The duodenum of the BBS-L group of mice has severe bleeding, congestion, intestinal villus breakage, disintegration and massive inflammatory cell infiltration. Furthermore, as shown in fig. 16, in terms of histological score, MG mice have a duodenal pathology score significantly higher than VG (P < 0.05), while BBS-H group and CG are significantly lower than MG (P < 0.05). Results show that BBS-H doses can alleviate pathogenicity e₁The pathological damage to duodenum of a diarrhea mouse is slightly better than that of ciprofloxacin. The jejunum, ileum and duodenum have similar trends.

5.3.2 Effect on Flock Length, crypt depth and ratios in mice with E.coli-induced diarrhea

As can be seen from FIG. 17, the villus length, crypt depth and V/C pole of MG duodenum were significantly lower than that of VG (P < 0.001), BBS-H and CG were significantly higher than that of MG (P < 0.001), BBS-H was the most effective, significantly higher than BBS-M, BBS-L (P < 0.05 or P < 0.01), and comparable to ciprofloxacin. The jejunum, ileal villus length, crypt depth and V/C changes have similar trends as the duodenum.

5.3.3 Effect on intestinal ultrastructure in mice with colibacillosis

As can be seen from FIGS. 18-20, the microvilli of the VG mouse duodenal epithelial cells are regularly and tightly arranged, the epithelial cell membrane and the nuclear membrane are intact, and the nucleoli is clearly visible; in the cytoplasm, the endoplasmic reticulum and mitochondria are clearly visible, and the intercellular tight junctions are not significantly broadened. The microvilli on the surface of MG intestinal epithelial cells are broken, disintegrated, sparsely arranged, different in length, and the tight connection between cells is obviously widened. And the duodenal epithelial cell membrane of BBS-H and CG mice is complete, the cell morphology is more normal, and the microvilli distribution rule is regular. The microvilli of duodenum of BBS-M mice slightly falls off, and the tight connection of the intestinal epithelium is slightly widened. The micro villi of the BBS-L duodenum are broken, disintegrated and sparsely arranged. Namely, the BBS treatment and maintenance of the ultrastructure of duodenum epithelium is slightly superior to that of ciprofloxacin. The change in the ultrastructure of the jejunum, ileum intestine has a similar tendency to that of the duodenum.

5.3.4 Occludin assay results

As can be seen from fig. 21, the Occludin protein expression in VGs was evenly distributed at the margins of the intestinal epithelial cells. Occludin staining in MG is uneven, and Occludin protein expression is obviously reduced. According to the RT-PCR result, the MG duodenal mucosal Occludin protein expression is obviously lower than that of VG (P < 0.001). BBS-H is better, and is obviously higher than BBS-M, BBS-L (P < 0.05 or P < 0.01), and is equivalent to ciprofloxacin.

5.3.5 Claudin-1 detection result

As can be seen from FIG. 22, the expression of Claudin-1 protein in VG was uniformly distributed on the margins of intestinal epithelial cells. Claudin-1 staining distribution in MG is uneven, and Claudin-1 protein expression is obviously reduced. The expression of Claudin-1 protein in the drug treatment group is improved to different degrees, wherein the BBS effect of the Mongolian veterinary drug is the best. According to the result of RT-PCR, the expression of Claudin-1mRNA in the duodenum of MG is reduced greatly (P < 0.001). The expression quantity of each group of Claudin-1mRNA is obviously or extremely higher than that of MG (P is less than 0.01 or P is less than 0.05), and BBS-H is superior to ciprofloxacin.

5.3.6 Zo-1 test results

WB results As shown in FIG. 23, ZO-1 protein expression levels in MG duodenum were significantly lower than VG (p < 0.05). The expression level of BBS-H ZO-1 protein is obviously higher than that of MG (p < 0.05). RT-PCR results showed that MG-duodenum ZO-1mRNA expression levels were very much lower than VG (p < 0.001). The expression level of ZO-1mRNA in the BBS-H, BBS-M, CG group is remarkably or extremely remarkably higher than that of MG (p < 0.01 or p < 0.05), wherein the Mongolian veterinary drug BBS-H, BBS-M has the best effect.

5.3.7 JAMA test results

WB results As shown in FIG. 24, JAMA protein expression levels in MG duodenum were significantly lower than VG (p < 0.001). The JAMA protein expression level in duodenum of mice in BBS-H group is obviously higher than that in MG (p is less than 0.05). According to the RT-PCR result, the JAMA mRNA expression level in the MG duodenum tissue is extremely lower than VG (p is less than 0.001), the JAMA mRNA expression level of each treatment group is remarkably or extremely higher than MG (p is less than 0.01 or p is less than 0.05), and the Mongolian veterinary drug BBS-H has the optimal effect.

5.3.8 MLCK detection result

WB results As shown in FIG. 25, MLCK protein expression levels in MG duodenum were significantly lower than VG (p < 0.001). The expression level of the MLCK protein in duodenum of the BBS-H group is obviously higher than that of MG. RT-PCR results showed that the expression level of MLCK mRNA in MG duodenal tissue was significantly lower than that of VG (p < 0.05). The expression level of MLCK mRNA in duodenal tissues of each treatment group is remarkably or extremely remarkably higher than that of MG (p < 0.01 or p < 0.05), and the Mongolian veterinary drug BBS-H has the optimal effect.

5.3.9 DAO, D-LA and ET detection results

As can be seen from FIG. 26, the content of DAO, D-LA and ET in MG serum was significantly higher than that of VG (p < 0.001). The content of DAO in the blood serum of each treatment group is remarkably or extremely lower than that of MG (p is less than 0.01 or less than 0.05), wherein the BBS-H effect of the Mongolian veterinary drug is optimal.

5.4 conclusion

Mongolian medicine BBS compound for effectively repairing pathogenicity E₁The intestinal physiological damage caused by the intestinal injury can be improved, and the villus width and crypt depth of the intestine and VCR can be improved to maintain the absorption and digestion functions of the small intestine and improveColi O reduction of pathogenicity by expression of Claudin-1, Occludin, ZO-1, JAMA-A, MLCK proteins related to tight junctions₁Resulting in increased permeability of the intestinal mucosa in mice, thereby repairing the damaged intestinal mucosal barrier.

Influence of 6 Mongolian veterinary drug BBS compound on intestinal mucosal immune barrier of mice with colibacillosis diarrhea

6.1 Experimental materials

6.1.1 reagents and consumables

Pharmingen^TMLeukocyte Activation Cocktail with BD GolgiPlug^TMStimulants, Pharmingen^TM Transcription Factor Buffer Set Buffer，IntraSure^TMKit rupture agents, FACS hemolysin, both from BD corporation; FITC-anti-CD8, PE-anti-CD3, FITC-anti-CD19, APC-anti-CD4, APC-anti-IFN-. gamma., PE-anti-IL-4, PE-anti-IL-17 were purchased from Biolegend; IL-2, IL-4, IL-6, IL-10, IL-17, IL-23, IFN-gamma, TNF-alpha, IgA, IgG, IgM, C3, C4, sIgA ELISA kits were purchased from Wuhan enzyme immunoassay Biotech, Inc.

6.1.2 the experimental species and animals were as in example 3.

6.2 Experimental methods

6.2.1 preparation of BBS compound as Mongolian veterinary drug, culture of tested bacteria, grouping experiments and administration scheme are the same as example 3.

6.2.2 Experimental procedures and sample Collection

Mice were anesthetized and 1mL of blood was collected from the eyeballs of heparin sodium anticoagulant vacuum blood collection tubes for flow cytometry. Then, 1mL of the heart blood is collected in a procoagulant blood collection tube, the heart blood is kept stand for 60min at room temperature, is centrifuged for 15min at 3000r/min, and serum is collected and subpackaged for subsequent experiments such as immunoglobulin and complement detection and the like. And taking duodenum to prepare tissue homogenate for detecting inflammatory factors.

6.2.3 flow cytometry

(1) Adding 1 × hemolysin into 200 μ L of anticoagulated blood at a ratio of 1: 10, mixing, standing at room temperature until blood becomes cool and transparent, and centrifuging at 1500g for 7 min; discarding the supernatant, and repeating the above steps if there is red precipitate at the bottom of the tube until there is no red precipitate;

(2) adding 3ml PBS for washing once, suspending and oscillating, and centrifuging for 7min at 1500 g; discarding the supernatant, and repeating the above steps for 2 times;

(3) diluting with 150 μ LPBS to adjust cell concentration to 1 × 10⁶mu/L;

(4) dividing the solution into two parts, adding 50 mu L of the solution into a sample loading tube, respectively adding 10 mu L of mouse lymphocyte fluorescence labeling antibody APC-anti-CD4/FITC-anti-CD8, PE-anti-CD3/FITC-anti-CD19, and labeling the mixture for 30min at room temperature in a dark place;

(5) repeating the step (2);

(6) adding 200 μ LPBS into the precipitate, suspending and oscillating, and detecting CD3 with flow cytometry⁺T、CD4⁺T、CD8⁺T and CD19⁺Percentage of B cells.

6.2.4 flow cytometry (TH1, TH2)

(1) Blood sampling: 1-2 mL of mouse peripheral blood whole blood is taken from a heparin sodium vacuum anticoagulation blood collection tube (the blood is placed at room temperature, the detection is carried out within 8h, otherwise, the blood is discarded);

(2) taking one sample as an example: taking 2 branch flow tubes, numbering in sequence (tube A: stimulation and non-staining for constant voltage, tube B: stimulant + IFN-gamma + IL-4 antibody), adding 200 μ L of anticoagulated whole blood into each tube (after lysing erythrocytes, the leukocyte concentration reaches 2 × 10)⁶Cells/ml), adding 4 mu L of stimulating agent into each tube of sample, uniformly mixing by vortex, and incubating for 4-6 h at 37 ℃ in a 5% CO2 incubator or 37 ℃ water bath;

note that: simultaneously taking another 2 branch flow type tubes, numbering in sequence (UA tube: unstimulated and unstained; UB tube: unstimulated + IFN-gamma + IL-4 antibody), adding 200 mu L of the same blood sample into each branch flow type tube without adding stimulant;

(3) cell surface marker staining: adding 20 μ L of CD4 antibody to each sample tube (A, B, UA, UB), vortexing, and incubating at room temperature in the dark for 15min (20-25 deg.C);

(4) each test tube had 4: (A, B and UA, UB) 100. mu.L of solution A (BD IntraSure Kit) was added, vortexed, and incubated at room temperature in the dark for 5min (20-25 ℃);

(5) hemolysis: adding 2ml of prepared 1X BD FACS hemolysin into each test tube (4 tubes: A, B, UA and UB), vortex, mixing, centrifuging at 6800g for 5min at room temperature and 10min in dark (20-25 deg.C), and discarding supernatant;

(6) 50 μ LB (BD IntraSure Kit) was added to each tube (4: A, B and UA, UB), and intracellular antibodies: tube A: IL-4 PE 20. mu.L, IFN-. gamma.APC 5. mu.L. Vortex, mix evenly, incubate for 30min in dark at room temperature;

(7) 2mL PBS was added to each tube (4: A, B and UA, UB), vortexed at low speed, 800g, centrifuged for 5min, and the supernatant discarded.

(8) 500. mu.L of PBS was added to each tube (4: A, B and UA, UB) and tested on the machine.

(9) 10000 cells of CD4+ were obtained and analyzed by flow cytometry under adjusted conditions (cell- > Instrument Setting called Calibur 4 color LNW).

6.2.5 ELISA

Preparing mouse serum, subpackaging and detecting the contents of IgA, IgG and IgM according to the description of an ELISA kit. Preparing duodenum tissue homogenate to detect the content of IL-2, IL-4, IL-6, IL-10, IL-17, IL-23, IFN-gamma, TNF-alpha and sIgA.

6.3 data processing is as above.

6.4 results of the experiment

6.4.1 CD3⁺T、CD19⁺Percentage of B cells assay results

As can be seen in FIGS. 27-28, CD3⁺T cell, MG mouse peripheral blood CD3⁺The percentage of T cells was very significantly lower than VG (P < 0.001); the percentage of CD3+ T cells in peripheral blood of each treatment group is remarkably or extremely remarkably higher than that of MG (P < 0.01 or P < 0.05), and BBS-H has optimal effect (P < 0.001). CD19⁺B cells, CD19 in MG mouse peripheral blood⁺The percentage of B cells was very significantly lower than VG (P < 0.001); CG. BBS-H, BBS-M mouse peripheral blood CD19⁺The percentage of B cells is all significant or very significant compared with MG (P < 0.01 or P < 0.05), and the BBS-H group has the best effect (P < 0.001).

6.4.2 CD4⁺T、CD8⁺Percentage of T cells assay results

As can be seen in FIGS. 29-30, CD4⁺T cell, MG mouse peripheral blood CD4⁺The percentage of T cells was very significantly lower than VG (P < 0.001); peripheral blood CD4 of mice of each treatment group⁺The percentage of T cells is all significantly or very significantly higher than that of MG (P <)0.01 or P < 0.05), wherein BBS-H is most effective. CD8⁺T cell, MG mouse peripheral blood CD8⁺The percentage of T cells was very significantly lower than VG (P < 0.001); peripheral blood CD8 of mice of each treatment group⁺The percentage of T cells is all significantly or very significantly higher than MG (P < 0.01 or P < 0.05), with the BBS-H group being the most effective. CD4⁺/CD8⁺CD4 in MG mouse peripheral blood⁺/CD8⁺The ratio of (A) is very significantly lower than that of VG (P < 0.05); the remaining treatment groups were CD4⁺/CD8⁺The ratios are all significantly higher than MG (P < 0.05), and the differences among groups are not significant (P > 0.05).

6.4.3 Th₁、Th₂Results of cell detection

As can be seen from FIGS. 31 to 32, Th₁Cell, Th in peripheral blood of MG mice₁The percentage of cells was very significantly higher than VG (P < 0.001); peripheral blood Th of each treatment group₁The percentage of cells is all remarkably or extremely remarkably lower than that of MG (P < 0.01 or P < 0.05), and BBS-H has the optimal effect (P < 0.001). Th₂Cell, Th in peripheral blood of MG mice₂The percentage of cells was very much lower than VG (P < 0.001); CG. BBS-H, BBS-M mouse peripheral blood Th₂The percentage of cells was all significantly or very significantly higher than MG (P < 0.01 or P < 0.05), with the BS-H group being the most effective (P < 0.001).

6.4.4 cytokine assay results

As can be seen from FIG. 33, the IL-1. beta. content, that of MG mice, was significantly higher than that of VG (P < 0.001); except BBS-L, the IL-1 beta content of mice in each treatment group is obvious or extremely lower than that of MG (P < 0.01 or P < 0.05), wherein the Mongolian medicine babu-7 treatment group has the best effect. IL-6 content, MG mice were significantly higher than VG (P < 0.001); the mice in each treatment group are remarkably or extremely remarkably lower than MG (P < 0.01 or P < 0.05), and BBS-H has the optimal effect (P < 0.05). The TNF-alpha content of MG mice is remarkably higher than VG (P is less than 0.01); each treatment group was significantly or very significantly lower than MG (P < 0.01 or P < 0.05), with BBS-H being the most effective (P < 0.01). The IL-10 content of MG mice is remarkably higher than that of VG (P is less than 0.001); each treatment group was significantly or very significantly lower than MG (P < 0.01 or P < 0.05), with the best BBS-H effect (P < 0.05). IL-4 content, MG mouse IL-4 content is significantly lower than VG (P < 0.01); compared with MG, each treatment group except BBS-H group is significantly or very significantly higher than MG (P < 0.01 or P < 0.05), and BBS-H has optimal effect (P < 0.001). IFN-gamma content, wherein the MG mouse IFN-gamma content is very much lower than VG (P is less than 0.01); except BBS-L, the other treatment groups are obviously or extremely obviously higher than MG (P < 0.01 or P < 0.05), and the BBS-H effect is optimal. TGF-beta content, MG mouse TGF-B content is very much lower than VG (P < 0.01); except BBS-H, the other treatment groups are remarkably or extremely remarkably higher than MG (P < 0.01 or P < 0.05), and BBS-H has the optimal effect (P < 0.01). IL-23 levels, compared to VG, in MG mice IL-23 levels were significantly elevated, with BBS-H being the most effective (P < 0.001). Each treatment group was significantly or very significantly lower than MG (P < 0.01 or P < 0.05), with the best BBS-H effect (P < 0.001). The IL-17 content of MG mice is obviously higher than that of VG (P is less than 0.01); the IL-17 content of mice in each treatment group is obvious or extremely lower than that of MG (P < 0.01 or P < 0.05), and the BBS-H effect is optimal. IL-8 content, MG mouse IL-8 content significantly higher than VG (P < 0.01); the IL-8 content of mice in each treatment group is remarkably or extremely lower than that of MG (P < 0.01 or P < 0.05), and BBS-H, BBS-M has the optimal effect. IL-2 content, MG mouse IL-2 content is significantly lower than VG (P < 0.001); the IL-2 content of mice in each treatment group is remarkably or extremely remarkably higher than VG (P < 0.01 or P < 0.05), and BBS-H is equivalent to ciprofloxacin (P < 0.001). The NO content in the peripheral blood of the MG mouse is remarkably higher than that of VG (P is less than 0.001); each treatment group was significantly or very significantly lower than MG (P < 0.01 or P < 0.05), with BBS-H being the most effective (P < 0.001).

6.4.5 immunoglobulin assay results

As can be seen from FIG. 34, IgA content, MG mouse peripheral blood IgA content, is significantly lower than VG (P < 0.01); besides BBS-L, the effect of BBS-H is optimal, and the effect of BBS-H is remarkably or extremely remarkably higher than that of MG (P < 0.01 or P < 0.05) in each treatment group of mice. IgG content, MG mouse peripheral blood IgG content is obviously lower than VG, and the Mongolian veterinary drug BBS treatment group is obviously higher than MG (P < 0.01 or P < 0.05). BBS-H is most effective (P is less than 0.001). The IgM content, namely MG mouse peripheral blood IgM content, is significantly lower than VG, and each treatment group is significantly higher than MG (P < 0.01 or P < 0.05). BBS-H, BBS-M works optimally (P < 0.001).

6.4.6 sIgA test results

As can be seen in FIG. 35, the duodenal sIgA content, the MG group, was very significantly lower than VG (P < 0.001); each treatment group was significantly or very significantly elevated over MG (P < 0.01 or P < 0.05), with BBS-H being the most effective. The sIgA content in the jejunum, MG mice are significantly lower than VG (P < 0.001); except for ciprofloxacin, the mice of each treatment group are obviously or extremely obviously higher than MG (P < 0.01 or P < 0.05), and the BBS-H effect is optimal. The sIgA content in ileum, MG mice are significantly lower than VG (P < 0.001); each treatment group was significantly or very significantly higher than MG (P < 0.01 or P < 0.05), with BBS-H being the most effective.

6.5 conclusion

The BBS of Mongolian veterinary drug is used for improving CD4⁺/CD8⁺And CD19⁺Percentage of B lymphocytes, increasing immunoglobulin and sIgA contents in mouse and correcting pathogenicity E₁Imbalance of Th1 and Th2 cells and their cytokines caused by invasion can improve animal immunity, thereby resisting pathogenicity E₁Resulting in damage to the intestinal immune barrier.

The present invention has been described in detail, but the above description is only a preferred embodiment of the present invention, and is not to be construed as limiting the scope of the present invention. All equivalent changes and modifications made within the scope of the present invention shall fall within the scope of the present invention.